X-SCID Gene Therapy Risks Not Generalizable To Other Conditions, Cmte. Says
This article was originally published in The Pink Sheet Daily
Executive Summary
FDA's Cellular, Tissue & Gene Therapies Advisory Committee points to unique factors in the biological basis of X-linked severe combined immunodeficiency disorder and the fact that leukemia cases have been seen in only one study.